Influenza Vaccine Elicits Acceptable Immunity in Ferrets

A novel influenza vaccine, which is delivered nasally, has been found to trigger robust immunity in ferrets, say researchers.

Researchers have revealed that a novel influenza vaccine, which is delivered nasally, has been found to trigger robust immunity in ferrets.

Experts at NanoBio Corporation have revealed that the immune responses elicited by the new vaccine were more than 20 times higher than those generated by two injections of the currently approved vaccines.

Hepatitis B-Causes-Symptoms-Diagnosis-Treatment-Vaccination-FAQs
Hepatitis B is inflammation of the liver due to infection with the hepatitis B virus.

The researchers also revealed that their intranasal vaccine used only half the standard antigen dose to produce that effect.

According to them, their nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.

"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp.

About Cholera
Cholera is an infection of the small intestine and is caused by the bacterium Vibrio cholerae.

"The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity," he added.

During the study, the team gave ferrets 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine, and found all three doses to produce antibody responses substantially higher than those triggered by the standard intramuscular vaccine.

Study Says Vaccinating Family may Help Protect Newborns Against Flu
Vaccinating new mothers and other family members against influenza can protect newborns against the life-threatening virus, say researchers from Duke Children's Hospital.

The ferrets, which represented the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.

"A large, unmet medical need still exists for protecting people from influenza infection. The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic," Baker said.

GAVI Alliance Says Vaccination Programmes Avert 3.4 Million Deaths
Immunisation programmes against meningitis and hepatitis in the world's poorest countries will have averted 3.

NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009, and is currently initiating pre-clinical studies in pandemic flu.

The results of the study were presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

Source-ANI
RAS/SK